九源基因(02566.HK)2024年收益13.69億元 同比增長6.4%
格隆匯3月26日丨九源基因(02566.HK)公告,截至2024年12月31日止年度年度業績,收益爲人民幣13.69億元,同比增長6.4%。公司擁有人應佔年內溢利爲人民幣1.39億元,較2023年的人民幣1.2億元增長人民幣1880萬元。每股基本盈利約爲人民幣0.68元,較2023年的人民幣0.60元有所增長。
生物藥(械)產品收入人民幣10.77億元,佔總收入超過78%。其中骨科產品收入同比增長超過19%,2021年至2024年年複合增長率超33%,業務收入持續快速增長,再創歷史新高。截至2024年12月31日止年度,中國市場目標醫療機構覆蓋率達到32.5%,骨優導產品滲透率不斷提高。
骨優導產品2024年保持較高增速,主要得益於:公司持續推進專業化學術推廣,組織骨科加速康復培訓交流、學術沙龍、院間交流會等活動,進一步規範和教育骨優導的臨牀使用方法,讓更多患者從骨優導卓越的臨牀治療中獲益;加快骨優導學術推廣人員的擴充和培養,依託多層次專業化培訓體系提高了人員專業化素質;持續推動空白和地縣市場覆蓋,實現骨優導全國省級市場全覆蓋,地縣級市場的二、三級目標醫院覆蓋率得到顯著提升。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.